Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

Study reveals gaps in epilepsy guidance compliance
MRI of Cavalier King Charles spaniel with seizures. Reproduced from BSAVA Manual of Canine Practice © BSAVA.

Researchers review more than three million electronic health records from UK veterinary practices.

An investigation into how UK primary care clinicians approach the initial management of canine generalised epileptic seizures has highlighted a number of gaps in compliance with current recommendations.

The study, published in the Journal of Small Animal Practice (JSAP), includes factors potentially associated with the prescription and choice of anti-seizure drugs. 

Using the Small Animal Veterinary Surveillance Network, the authors reviewed more than three million electronic health records from over 200 veterinary practices. A total of 517 cases were included in the study, with dogs older than six years excluded. 

The paper reveals that 13 per cent of the dogs received anti-seizure drugs at first presentation; the odds of administering anti-seizure drugs were about 14 times larger in dogs presented with cluster seizures.

It also shows that the most commonly selected anti-seizure drugs were imepitoin and phenobarbital. Of the dogs presenting with a single seizure and at least a six-month follow-up, 20 per cent did not have subsequent seizures recorded.

In line with International Veterinary Epilepsy Task Force recommendations, anti-seizure drugs following a single epileptic seizure were rarely prescribed. They were also only prescribed to fewer than half the dogs initially presenting with cluster seizures.

Despite no authorisation for this purpose, Imepitoin was often chosen for the treatment of cluster seizures.

Commenting on the findings, JSAP editor Nicola Di Girolamo, said: “Studies like this one are instrumental to understand how primary care clinicians comply with current recommendations. Additional efforts may be required to fully adhere to the International Veterinary Epilepsy Task Force recommendations; being aware of these gaps is the first step towards improvement.”

Become a member or log in to add this story to your CPD history

Annual submission deadline small pet animal exemptions

News Story 1
 Companies marketing medicines for small pets exempt from authorisation must submit their annual return to the Veterinary Medicines Directorate (VMD) by 30 November 2026.

Submitting this annual return ensures continued compliance with regulatory requirements for products marketed without a full Marketing Authorisation. The exemption specifically applies to products intended for animals, cage birds, terrarium animals, small rodents, ferrets and rabbits.

For further details and submission guidelines, visit the gov.uk website.  

Click here for more...
News Shorts
Bluetongue RZ extended across Scotland

The Scottish Government has announced an extension to a Bluetongue Restricted Zone that is in place in south-west Scotland.

From 3 October, the Restricted Zone will be extended to cover the whole of Scotland. The Animal, Plant and Health Agency (APHA) says this is in response to further disease spread, as well as simplify trading conditions ahead of the autumn.

Since the whole country will share a disease status, it will no longer be necessary to have a movement license to move susceptible livestock around the country. Restrictions on germinal products remain.

As of 1 October 2026, there were 1,979 cases of BTV-3 in England, 389 cases in Wales and 40 cases in Scotland.